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Microvascular function and 
oxidative stress in adult individuals 
with early onset of cardiovascular 
disease
Hala Shokr1, irundika H. K Dias2 & Doina Gherghel1*
the current study aims to investigate retinal vascular function and its relationship with systemic 
anti-oxidative defence capacity in normal individuals versus those with early hypertensive changes 
according to the current ESC/ESH guidelines. Retinal microvascular function was assessed in 201 
participants by means of dynamic retinal vessel analysis. Blood pressure, lipid panel, oxidized (GSH) 
& reduced glutathione (GSSG) were also evaluated for each participant. individuals classed as grade 
1 hypertension demonstrated higher retinal arterial baseline diameter fluctuation (p = 0.0012), 
maximum dilation percentage (p = 0.0007), time to maximum constriction (p = 0.0003) and lower 
arterial constriction slope (p = 0.0131). Individuals classed as high normal and grade 1 hypertension 
also demonstrated higher time to maximum dilation than individuals classed as optimal or normal. GSH 
levels correlated negatively with SBp, DBp and MBp values in all participants (p = 0.0010; p = 0.0350 
and p = 0.0050) as well as with MBP values in high normal and grade 1 hypertension (p = 0.0290). The 
levels of GSSG correlated positively with SBp, DBp and MBp values in all participants (p = 0.0410; 
p = 0.0330 and, p = 0.0220). Our results point to the fact that microvascular alterations can be 
identifiable at BP values still considered within normal values and go in parallel with the changes 
observed in the level of oxidative stress.
The assessment of the microvascular function represents an important part in establishing the pathophysiology 
but also the risk stratification of cardiovascular disease (CVD)1. Indeed, endothelial dysfunction, one of the main 
culprits for the development of atherosclerosis, occurs much earlier at the microvascular than at the macrovascu-
lar level2,3. Dynamic retinal vessel analysis (DVA) was identified as a useful measure of early changes that signal 
endothelial dysfunction at the microvascular level. This method can also be used to identify risk for future car-
diovascular pathologies in individuals at risk for4–9 or already suffering from CVD10,11. This is generally possible 
due to the fact that the retinal microvascular response to flicker provocation is, in part, dependent on nitric oxide 
(NO) release12, and compromised NO homoeostasis is known to be a key factor in endothelial dysfunction at all 
vascular levels.
The assessment of retinal microvessels is used in research but also in clinical practice for diagnosis and 
follow-up of various CVD, including hypertension13,14. Nevertheless, the overwhelming majority of protocols 
that look at retinal microvessels in the course of various CVD, use static imaging to detect abnormalities associ-
ated with various degrees of pathology. This is, however, useful only when CVD already established itself and not 
at earlier, pre-clinical stages. In order to determine the risk at earlier stages to allow preventive measures to be 
adopted, using the assessment of the retinal microvascular function represents a better alternative to structural 
imaging because it provides integrated and dynamic data to help establishing possible CVD risk.
In certain conditions that accelerate degradation of NO, such as high oxidative stress, microvascular dila-
tion can be severely impaired15. In order to counteract such effects, the human body uses various anti-oxidative 
mechanisms including glutathione. Therefore, any condition associated with low levels of circulating glutathione 
result in a higher rate of oxidative reactions that contribute towards low NO bioavailability and, consequently, 
to an impaired microvascular function5,8,16,17. We have already shown that retinal microvascular dilation and 
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constriction responses to stress levels are influenced by systemic antioxidant capacity, and circulating markers 
for CVD risk in healthy individuals with low to moderate cardiovascular risk7. Moreover, we have suggested that, 
by providing an integrated and dynamic analysis of vascular function that is, indeed, specific for each individ-
ual, retinal vessel reactivity could also be used for profiling a so-called individualized vascular risk for CVD7,8. 
Nevertheless, we have not tested this hypothesis in individuals with early stages of CVD. Therefore, the present 
study aims to study the retinal vascular function and its relationship with systemic anti-oxidative markers in 
individuals with various levels of early BP abnormalities as defined according to the 2018 European Society of 
Cardiology/European Society of Hypertension Guidelines18.
Methods
Study participants. Healthy individuals over the age of 30 were recruited through advertisements at the 
Vascular Research Laboratory, Aston University (Birmingham, UK), for inclusion in this prospective study. 
Ethical approval was sought from the relevant local ethics committee, and written informed consent was 
received from all participants prior to study enrolment. All experimental protocols were approved by the Aston 
University’s Ethics Committee and the study was designed and conducted in accordance with the tenets of the 
Declaration of Helsinki.
Study exclusion criteria were defined as the positive diagnosis of CVD, (coronary artery disease, heart fail-
ure, arrhythmia, stroke, transient ischaemic attacks), cerebrovascular disease, peripheral vascular disease, severe 
dyslipidaemia (defined as plasma triglycerides > 6.00 mmol/l or cholesterol levels > 7.00 mmol/l), diabetes, as 
well as other metabolic disorders or chronic diseases that required treatment. Individuals treated for systemic 
hypertension as well as those using other vasoactive medications such as dietary supplements containing vitamins 
or antioxidants and bronchodilators were also excluded from the study. Potential participants were also screened 
for ocular diseases and were excluded from the study if they had a refractive error of more than ± 3DS and more 
than ± 1DC equivalent, intra‐ocular pressure (IOP) greater than 21 mmHg, cataract or any other media opacities, 
as well as history of intra‐ocular surgery or any form of retinal or neuro‐ophthalmic disease affecting the ocular 
vascular system. Individuals with sings of hypertensive retinopathy at the initial fundus examination were also 
excluded.
All the above investigations are standard for our lab7,8,19–21.
General investigations. Participants who met the inclusion criteria were requested to complete a general 
health history questionnaire, also detailing daily diet, physical activity and alcohol consumption. All study‐related 
measurements were performed between 8 and 11 am following a 12‐hr overnight fast, which included refraining 
from alcohol and caffeine.
Standard anthropometric measures of height and weight were recorded to determine body mass index 
(BMI = weight/height²).
Blood pressure assessment and patients grouping. Measurements of BP and heart activity were first 
perdormed in-clinic. They were then confirmed using a computer‐operated ambulatory BP and electrocardio-
gram (ECG) monitor (Cardiotens‐01, Meditech Ltd, Budapest, Hungary). This device measures BP automati-
cally using an oscillometric method and can store 1000 BP measurements. All subjects maintained their normal 
activity and were carefully instructed to complete a diary each time their activities changed, or when any chronic 
medication was taken. The 24‐h BP were later downloaded and analysed using the ‘Medibase’ software program 
(Meditech). The average systolic (SBP) as well as diastolic BP (DBP) measurements were calculated for the 24‐h 
interval and for both the active and passive periods of the recording. The average readings for SBP and DBP were 
then used to calculate the mean BP (MBP) using the formula: MBP = 2/3 × DBP + 1/3 × SBP. At least 80% of the 
programmed recordings were required for a diurnal curve to be considered in the present analysis22.
Using the 24-h SBP and DBP values, study participants were then stratified into four subcategories, ‘’optimal ‘’ 
“normal”, “high normal” and ‘’Grade I” as recommended by the 2018 European Society of Cardiology/European 
Society of Hypertension arterial hypertension Guidelines18.
Dynamic retinal vessel analysis. Retinal vessel reactivity was assessed using the dynamic retinal ves-
sel analyser (DVA, IMEDOS GmbH, Jena, Germany) in accordance with an established protocol23. All meas-
urements were performed in a temperature-controlled environment (22 °C) following pupil dilation with 1% 
Tropicamide (Chauvin Pharmaceuticals Ltd, UK) and were taken from the inferior temporal vessel branches 
approximately one and a half disc diameters from the optic nerve head of one unselected eye. The flicker stimula-
tion protocol involves a 350‐second continuous diameter recording along short 1 mm sections of the retinal vas-
culature, the duration of which included a 50‐second baseline measurement followed by three successive cycles 
of flicker stimulation distinguished as a 20‐second stimulus (opto‐electronically generated at 12.5 Hz) and an 
80‐second recovery period (still illumination)7. The following vessel reactivity and time-course parameters were 
determined for each flicker cycle and then averaged over the 3 cycles, with the artery and vein regarded separately 
as follows: the average baseline diameter and range of maximum and minimum baseline vessel diameters (base-
line diameter fluctuation, BDF); the maximum vessel dilation diameter during flicker stimulation expressed as 
a percentage change relative to baseline diameter (MD%) and the time taken in seconds to reach the maximum 
diameter (tMD); the maximum vessel constriction diameter during the postflicker recovery period expressed as a 
percentage change relative to baseline diameter (MC%) and the time taken in seconds to reach the maximum ves-
sel constriction diameter (tMC); the overall dilation amplitude (DA) calculated as the difference between MD and 
MC; and the baseline-corrected flicker response (BCFR) used to describe the overall dilation amplitude after nor-
malizing for fluctuations in baseline diameters (DA-BDF). In addition, the arterial (A) and venous (V) dilation 
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slopes (SlopeAD/VD = (MD − baseline diameter)/tMD) and constriction slopes (SlopeAC/VC = (MC − MD)/tMC) 
were also calculated (Fig. 1)6.
Biomarker assays. Bloods samples drawn from the ante‐cubital fossa vein on the morning of the appoint-
ment were collected into standard EDTA Vacutainer® tubes and assessed immediately for fasting triglycerides 
(TG), plasma total cholesterol (CHOL) and high‐density lipoprotein cholesterol (HDL‐C) using the Reflotron 
Desktop Analyser (Roche Diagnostics, UK). Low‐density lipoprotein cholesterol (LDL‐C) values were calculated 
as per the Friedewald equation24.
Measurement of GSH and oxidized glutathione (GSSG). Initial processing of blood GSH and 
GSSG levels were assessed by the GSH recycling assay as detailed previously21. Briefly, a 30 μl aliquot of 
EDTA blood was pretreated with 33.3 μl of 100 mg/ml 5‐sulfosalicylic acid (SSA), 936.7 μl sodium phos-
phate buffer (pH 7.5) to release GSH via cellular disruption and protein precipitation. The sample was cen-
trifuged at 13, 000 rpm for 5 min, and the supernatant was stored at −80 °C for further analyses. Based on 
previous reports of sample stability, assays were conducted within 2 months of collection25. The GSH levels 
[t‐GSH – (2 × GSSG)] and the redox index (defined as the GSH/GSSG ratio) were determined according 
to an established enzymatic recycling assay26,27 that involves the oxidation of GSH by the sulphydryl rea-
gent 5,5′‐dithio‐bis(2‐nitrobenzoic acid) (DTNB) to form the yellow derivative 5′‐thio‐2‐nitrobenzoic acid 
(TNB), which can be measured spectrophotometrically at 412 nm.
Any GSSG formed was recycled to GSH by glutathione reductase (GSR) in the presence of nicotinamide 
adenine dinucleotide phosphate‐oxidase (NADPH). For the measurement of GSSG levels, samples were 
pretreated with, 2‐vinylpyridine (2VP) to derivatize GSH without interfering with GSR reaction. For the 
determination of analyte concentrations in the samples, GSH standards were prepared from 0 to 80 μm in 
increments of 20 μm and GSSG standards were prepared from 0 to 10 μm in increments of 1 μm with the 
same final concentrations of SSA (1%) as in the samples. Standard curves were generated using a linear 
regression program (Microsoft Excel, Microsoft Corporation, USA). As the microplates were read at 0, 1, 
2, 3 and 5 min, the change in optical density or absorbance at different times points expressed against GSH 
or GSSG concentration (net reaction rate = slope * GSH or GSSG concentration + intercept) was used to 
determine GSH or GSSG concentrations in the samples (net rate − intercept/slope * dilution factor). The 
blood GSH and GSSG concentrations measured in this study were in good agreement with literature data 
in control patients in the ranges of 150–1500 μm and 1–500 μm, respectively5,8,23,28,29. This suggests that the 
experimental conditions reported in this study are suitable for the analysis of total glutathione and glu-
tathione disulphide concentrations in whole blood. The validity and reliability of the spectrophotometric 
method of detection has also previously been established30.
Sample size and statistical analysis. Based on previous studies, a change of 30% with a SD of 2.5% in 
retinal vessels reactivity was shown to be significant8,31. As the study design was multifactorial in nature, it was 
calculated that a sample size of n = 42 in each group was sufficient to provide 95% power at an alpha level of 0.05.
All analyses were performed using Statistica® software (version 13.3, StatSoft Inc., Tusla, OK, USA). 
Distributions of continuous variables were determined by the Shapiro-Wilks test. In cases where normality 
of the data could not be confirmed appropriate data transformations were made or non-parametric statis-
tical alternatives were used. Univariate associations were determined using Pearson’s (normally distributed 
data) or Spearman’s method (non-normally distributed data), and forward stepwise regression analyses were 
performed to test the influence of clinical parameters and circulating markers on the measured vascular 
Figure 1. Graphical presentation of the dynamic vessel response profile displaying the parameters calculated 
and used in analysis. (DA) calculated as (MD-MC). (MD%) calculated as the percent increase from baseline to 
MD. (MC%) calculated as the percent constriction below baseline following MD42.
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reactivity variables. Differences between groups were subsequently assessed using one-way ANOVA or 
ANCOVA, as appropriate, followed by Tukey’s post hoc analysis. P-values of <0.05 were considered 
significant5–7.
Results
A total number of 218 participants were initially screened for study inclusion of which 17 individuals were 
excluded based on the quality of retinal vascular image analysis. The remaining 201 participants (93 men and 
108 women) were included in the final analysis and classified in one of 4 study groups using the current ESC/
ESH Guidelines: group 1 (optimal BP: 56 individuals 22 men and 34women), group 2 (normal BP: 54 individuals, 
35 men and 19 women), group 3 (high normal BP: 44 individuals, 28 men and 16 women) and group 4 (grade 1 
hypertension: 47 individuals, 28 men and 19 women).
Table 1 shows the clinical characteristics of the study population. Although the first group were significantly 
younger than group 4, there were no statistically significant differences between the study groups with regards 
to gender, BMI and circulating levels of glucose, t-Chol and HDL-Chol between the study groups (all p > 0.05). 
Nevertheless, as expected, there were statistically significant differences between the 4 study groups with regards 
to SBP, DBP and MBP (all p < 0.0001). In addition, individuals classed as high normal and grade 1 hypertension 
demonstrated higher levels of circulating TG (p = 0.0021, ANCOVA) and GSSG (p = 0.0111, ANCOVA) and 
lower levels of GSH (p = 0.0060, ANCOVA). Moreover, individuals classed as grade 1 hypertension demonstrated 
higher levels of LDL-C (p = 00265, ANCOVA) than the rest of the study groups.
With regards to arterial and venous retinal vascular reactivity parameters as characterized in Tables 2 and 3, all 
values reported are based on averaged data across three flicker cycles with the artery and vein regarded separately.
With regards to the measured retinal arteriolar parameters, after controlling for all influential covariates iden-
tified by multivariate regression analysis, and independent of age, individuals classed as grade 1 hypertension 
demonstrated significantly higher BDF (p = 0.0012, Fig. 2), MD% (p = 0.0007, Fig. 2), tMC (p = 0.0003, Fig. 2) 
and lower SlopeAC (p = 0.0131, Fig. 2) than the rest of the study groups. In addition, individuals classed as high 
normal and grade 1 hypertension also demonstrated higher tMD than individuals classed as optimal or normal 
(p < 0.0001, Fig. 2).
There were no significant differences between participants with regard to measured venous parameters (all 
p > 0.05, Table 3).
correlations between vascular and systemic circulatory parameters. Univariate analysis revealed 
that the whole blood GSH levels correlated significantly and negatively with SBP, DBP and MBP values in all 
participants (r = −0.25, p = 0.0010; r = −0.17, p = 0.0350 and r = −0.22, p = 0.0050, as well as with MBP values 
in those classed as high normal and with grade 1 hypertension (r = −0.38, p = 0.0290) but not in those classed 
as having optimal or normal BP (p > 0.05). In addition, the levels of whole blood GSSG correlated significantly 
and positively with SBP, DBP and MBP values in all participants (r = 0.16, p = 0.0410; r = 0.17, p = 0.0330 and 
r = 0.18, p = 0.0220,but not in any groups separately (all p > 0.05).
There were no correlations between the levels of GSH and retinal vascular parameters in any of the study groups 
(all p > 0.05). However, GSSG levels correlated significantly and positively with artery BDF (r = 030, p = 0.0370) 
and negatively with SlopeAC only in individuals classed as having an optimal BP level (r = −0.37, p = 0.0200).
Variable
Optimal (1) 
(Mean + SD)
Normal (2) 
(Mean + SD)
High-Normal (3) 
(Mean + SD)
Grade 1 (4) 
(Mean + SD) p-value Post –Hoc
Number 56 54 44 47 — —
Age (years) 40.25(1.80) 42.67(1.87) 46.50(2.06) 47.60(2.03) 0.0260* —
SBP (mmHg) 109.11(0.79) 124.59(0.82) 131.95(0.90) 145.31(0.90) 0.0000* 1 < 2 < 3 < 4
DBP (mmHg) 67.38(1.07) 74.71(1.11) 81.17(1.22) 87.59(1.22) 0.0000* 1 < 2 < 3 < 4
HR (bpm) 66.69(1.27) 67.61(1.32) 68.48(1.46) 70.24(1.46) 0.3149 —
IOP (mmHg) 14.31(0.82) 15.15(0.85) 16.76(0.93) 16.30(0.93) 0.1870 —
MAP (mmHg) 81.29(1.30) 91.33(1.35) 98.09(1.48) 104.35(1.47) 0.0000* 1 < 2 < 3 < 4
BMI (kg/m2) 25.32(0.90) 26.88(1.027) 27.89(0.99) 28.21(0.88) 0.0808 —
Glucose 4.77(0.12) 4.80(0.12) 4.90(0.14) 5.01(0.13) 0.4875 —
TG (mmol/L) 1.01(0.06) 1.15(0.06) 1.29(0.07) 1.43(0.07) 0.0021* 1 = 2 > 3,4 3 = 4
CHOL 4.53(0.13) 4.38(0.13) 4.62(0.15) 4.80(0.14) 0.1875 —
HDL-C (mmol/L) 1.21(0.07) 1.13(0.07) 1.19(0.08) 1.16(0.07) 0.6838 —
LDL-C (mmol/L) 2.92(0.15) 3.06(0.16) 3.27(0.18) 3.59(0.17) 0.0265* 1 = 2 = 3 < 4
GSH(umol) 712.37(68.79) 601.47(74.18) 412.52(77.17) 428.63(83.43) 0.0060* 1 = 2 > 3,4 3 = 4
GSSG(umol) 36.15(7.92) 55.53(8.54) 62.49(9.75) 76.67(9.47) 0.0111* 1 = 2 < 3,4 3 = 4
Table 1. Summary of the systemic characteristics of the study participants. Abbreviations: SBP: systolic blood 
pressure; DBP: diastolic blood pressure; HR: heart rate; IOP: intraocular pressure; BMI: body mass index; 
TG: triglycerides; CHOL: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein; GSSG: oxidized glutathione; GSH: reduced glutathione. *Significant p-values are indicated where  
p < 0.05 was considered significant.
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Discussions
In the present study, we have examined the differences in retinal vascular function between individuals with 
normal and early stages of abnormal BP according to the current ESC/ESH guidelines. We have also looked at the 
relationship between systemic BP, retinal vessel reactivity and systemic antioxidant defense capacity in each of the 
study groups. Our results showed, for the first time, that individuals graded as having high normal BP values or 
grade 1 hypertension displayed abnormal dilatory and constrictor responses to flicker light stimulation in retinal 
arteries but not in the retinal veins when compared to those classed as having optimal or normal BP values.
Hypertension is a polygenic disease; however, endothelial dysfunction and enhanced oxidative stress are 
among the established modifiable risk factors for this disease32. Alteration of vascular reactivity characterized by 
augmented contractility and impaired relaxation is a prominent feature in hypertension. Moreover, in essential 
hypertension, NO availability is reduced earlier, resulting in early vascular endothelial dysfunction33. Indeed, 
our relatively young patients with high normal BP and grade 1 hypertension according to the current ESC/EHS 
guidelines demonstrated abnormal retinal microvascular dilation and constriction after stimulation with flick-
ering light.
It has already been demonstrated that pre-hypertension is associated with retinal microvascular alterations 
early in life34. Nevertheless, it seems that these alterations can also be identifiable at BP values previously consid-
ered within normal values. Indeed, our study participants classed as having high normal BP values and without 
Variable
Optimal 
BP (1) 
(Mean + SD)
Normal 
BP (2) 
(Mean + SD)
High-Normal 
BP (3) 
(Mean + SD)
Grade 1 
BP (4) 
(Mean + SD)
p-value 
Anova/
Ancova Post-Hoc
Baseline 109.00(2.23) 110.42(2.48) 113.81(2.97) 111.77(4.45) 0.08319 —
BDF 5.36(0.40) 5.75 (0.42) 6.62(0.46) 8.12(0.46) 0.0012* 1 = 2 = 3 < 4
BCFR 4.62(0.40) 3.85(0.48) 4.08(0.53) 5.74(0.81) 0.2646 —
MD 114.22(2.44) 115.54(2.72) 119.86(3.25) 118.81(4.87) 0.1194 —
tMD 12.76(0.698) 14.77(0.735) 18.04(0.842) 23.10(0.79) 0.0000* 1 = 2 < 3 < 4
MD % 5.46(0.53) 4.31(0.58) 5.17(0.57) 7.31(0.513) 0.0007* 1 = 2 = 3 < 4
MC 106.14(2.39) 107.39(2.39) 110.35(3.18) 108.60(4.76) 0.2053
tMC 23.85(1.07) 25.40(1.109) 26.77(1.22) 30.84(1.22) 0.0003* 1 = 2 = 3 < 4
MC% −4.31(0.282) −3.63(0.293) −4.042(0.32) −3.23(0.32) 0.1696 —
DA 9.11(0.66) 9.04(0.735) 9.46(0.88) 11.32(1.35) 0.4951 —
SlopeAD 0.69(0.066) 0.57(0.069) 0.37(0.08) 0.51(0.075) 0.1539 —
SlopeAC −0.45(0.07) −0.44(0.07) −0.48(0.08) −0.74(0.08) 0.0131* 1 = 2 = 3 > 4
Table 2. Summary of retinal arterial vascular function parameters. Abbreviations: ANOVA, analysis of 
variance; ANCOVA, analysis of covariance; Baseline, baseline diameter; BDF, baseline diameter fluctuation; 
BCFR, Baseline corrected flicker response; tMD, time to reach MD; MD (%), percent dilation; tMC, time to 
reach MC; MC (%), percent constriction; DA, dilation amplitude (difference between MD and MC during 
flicker) SlopeAD, slope of arterial dilation; SlopeAC, slope of arterial constriction. *Significant p-values are 
indicated where p < 0.05 was considered significant.
Variable
Optimal BP (1) 
(Mean + SD)
Normal BP (2) 
(Mean + SD)
High-Normal BP 
(3) (Mean + SD)
Grade 1 BP (4) 
(Mean + SD)
p-value 
Anova/
Ancova
BL 146.41(3.93) 144.11(4.08) 151.22(4.50) 143.30(4.44) 0.5542
BDF 6.08(0.50) 4.769(0.60) 5.21(0.75) 6.51(0.93) 0.1913
BCFR 4.42(0.41) 4.21(0.43) 4.86(0.47) 3.88(0.47) 0.4718
MD 153.77(4.07) 152.77(4.18) 161.22(4.63) 152.10(4.59) 0.4623
tMD 19.97(0.79) 20.56(0.94) 21.18(1.198) 22.05(1.46) 0.0525
MD% 5.28(0.35) 5.44(0.37) 5.42(0.40) 6.10(0.41) 0.2231
MC 143.04(3.89) 141.74(4.038) 148.13(4.45) 140.56(4.40) 0.6051
tMC 34.30(1.29) 31.10(1.43) 32.90(1.70) 32.50(2.53) 0.4114
MC% −1.76(0.20) −1.57(0.22) −1.48(0.31) −1.90(0.38) 0.7218
DA 9.79(0.72) 8.61(0.73) 11.22(0.84) 11.16(0.83) 0.1069
SlopeVD 0.39(0.03) 0.38(0.04) 0.36(0.05) 0.41(0.056) 0.8740
SlopeVC −0.48(0.10) −0.39(0.11) −0.498(0.12) −0.83(0.12) 0.0663
Table 3. Summary of retinal venous vascular function parameters. Abbreviations ANOVA, analysis of variance; 
ANCOVA, analysis of covariance; Baseline, baseline diameter; BDF, baseline diameter fluctuation; BCFR, 
Baseline corrected flicker response; tMD, time to reach MD; MD (%), percent dilation; tMC, time to reach MC; 
MC (%), percent constriction; DA, dilation amplitude (difference between MD and MC during flicker) SlopeVD, 
slope of venous dilation; SlopeVC, slope of venous constriction. *Significant p-values are indicated where p < 
0.05 was considered significant.
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additional risks for CVD, have also exhibited signs of microvascular dysfunction at the retinal level. At these BP 
values, treatments for hypertension are not yet indicated; however, in the light of the above observations, addi-
tional measures to prevent further damage may be considered. Moreover, ESC/ESH also recommends treating 
at lower BP levels in very high-risk patients with a high–normal BP and established CVD18. Nevertheless, the 
potential impact of pushing for an earlier diagnosis is multiple, including pressures on the health system and 
economy35. Therefore, a careful consideration should be given to the actual benefits of treatment in each individ-
ual separately, rather than in a given risk category. At present, all the new biomarkers for CVD risk drive the shift 
towards personalized medicine. Therefore, due to its personalised approach, retinal vessel reactivity can be used 
for profiling individualized vascular risk by providing an integrated and dynamic analysis of vascular function 
specific for each individual, therefore, aiding a personalised management of abnormal BP values.
As already mentioned above, increased oxidative stress is an important risk factor for the development of 
hypertension. Among other defense mechanisms, glutathione represents a major redox buffer36. It has been 
already shown that GSH significantly lower and the GSSG is higher in the red blood cells in patients with hyper-
tension but not in normal individuals37. Similarly, we have also shown that whole-blood GSH level were lower 
and GSSG level were higher in individuals classed as high normal and grade 1 hypertension. These results show 
for the first time that such changes may actually occur at a much earlier stage than previously noticed and go in 
parallel in the changes observed in the retinal microvasculature, confirming that, in the presence of abnormal BP 
levels, the pathological inhibition of vascular relaxation involves not only NO production by endothelial cells but 
also a glutathione-dependent bioavailability of NO38. In addition, we also demonstrated that GSSG correlated 
with retinal arterial baseline and constriction characterisation parameters only in individuals with optimal BP 
levels and without additional CVD risks. It is very interesting that, although the levels of antioxidative products 
were abnormal in individuals with higher BP levels, the link between redox status and retinal vascular reactivity 
was lost in these groups. This observation links, however, to our previous results in in individuals with low to 
moderate CVD risk, indicating that in addition to other processes, antioxidant mechanisms support normal NO 
levels during flicker provocation at the retinal microvascular level7. However, in the present study we could not 
identify such relationship in individuals with higher levels of BP. As the effects of radical oxygen species (ROS) on 
vascular tone is dependent upon the concentration and type of species, as well as on the type of vascular beds and 
various experimental conditions39, it is possible that these effects were not visible in our specific setup. Indeed, it 
has been proposed that there is a lack of sensitive methods to accurately evaluate the oxidative stress in the human 
cardiovascular system, especially when it comes to establishing the role redox stress in the small artery vasculop-
athy of human hypertension40.
conclusions
Abnormalities of microvascular dysfunction may be an important risk factor for systemic hypertension. In addi-
tion, excessive oxidative stress is associated results in cardiovascular diseases by impairing endothelial func-
tion and, consequently, microvascular dysfunction. This complex interlink cannot be ignored and measures to 
address both dysfunctions should be applied. This is especially important since, despite significant advancement 
in understanding the pathophysiology of human hypertension and the large number of antihypertensive drugs, 
strict BP control is still proving insufficient for the prevention of future vascular complications, the so-called 
Figure 2. Comparison of retinal arterial response profile across groups. AU, arbitrary units; BDF, baseline 
diameter fluctuation calculated as the maximum range in vessel diameter during first 30 seconds of baseline 
readings; MD%, calculated as the percentage change in vessel diameter from baseline to maximum following 
onset of flicker; tMD, time to reach maximum diameter during flicker; tMC, time to reach maximum 
constriction post flicker; SlopeAC,,calculated as (MC-MD)/(tMC).
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“Hypertension Paradox”41. Therefore, more research is necessary to develop specific mechanism-based personal-
ised therapies that will address the vascular redox pathobiology40. These therapies will possibly need to be applied 
at much earlier stage when abnormalities are only functional and can still be reversed.
Data availability
The data that support the findings of this study are available on request from the corresponding author.
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